La jeune pousse du Biopôle d’Epalinges a bouclé un tour de table de série A, la semaine dernière. Stefan Catsicas, ancien cadre de Nestlé et de l’EPFL, rejoint son conseil d’administration.

Tiba Biotech, a preclinical biopharmaceutical company, today announced it has entered into a five-year, multi-million US dollar agreement with the Australian state government of New South Wales (NSW) to develop next-generation mRNA vaccines against emergency animal diseases that threaten Australia’s livestock industry and domestic food security.

Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological treatment option.

British agritech startup Tropic Biosciences has raised $35 million in fresh funding in its effort to pioneer gene-editing technology that protects crops such as coffee, bananas and rice from disease.

BCD Bioscience, a biotechnology company creating precision prebiotics from natural fibers, today announced that it has completed an oversubscribed Series A financing round of $12 million led by Acre Venture Partners.

Europe-based vertical farming firm Infarm this week announced a $200 million Series D. The round, led by the Qatar Investment Authority (QIA), follows last year’s $170 million raise.

Vedanta wrapped up a $68 million Series D raise Wednesday morning, which included the $25 million equity investment Pfizer plunked down back in January.

Poseida Therapeutics has joined Cellares’ Early Access Partnership Program (EAPP) to accelerate cell therapy manufacturing.

Aleph Farms Ltd., a startup that grew meat in space and printed the world’s first slaughter-free ribeye steak, has raised more than $100 million to bring its cultivated beef to the market as soon as next year.

Funding round is led by private equity firm L Catterton and DisruptAD, the VC arm of Abu Dhabi’s holding company ADQ.

Primary care startup Forward Health is looking to expand its tech-powered, personalized healthcare model across the U.S., and will use a new $225 million Series D raise to help make it happen.

The U.K.-based biotech raised £69.2 million ($95.4 million) from the likes of OrbiMed and GV to advance a pipeline of exosome-based treatments into the clinic and further develop the technology that underpins them.

Ukko recently announced a $40M Series B funding round to advance its efforts in ending food allergies for good. The funding Series was led by Leaps by Bayer—the impact investment arm of Bayer.

Under the partnership, PACT Pharma will provide the company with insight into autologous NeoTCR manufacturing workflows to help identify product-market fit and secure early access to the technology for an undisclosed amount

Six inventions for protecting our food with materials that protect the environment, too…

Evox to use its proprietary exosome loading and CNS-targeting technologies to develop oligonucleotide drugs for the treatment of neurological disorders…

Biotech startup Tropic Biosciences, which develops high-performance varieties of tropical crops, on Thursday said it has raised US$28.5 million in a Series B round led by Singapore state investment firm Temasek, bringing its total equity funding raised to US$40 million…

The antibody test, which has a potential time to result of 14 minutes, will join the rest of the company’s diagnostic portfolio…

A British start-up using the active ingredient in so-called magic mushrooms to treat clinical depression has raised $80 million from investors, including Peter Thiel, the billionaire Paypal co-founder and early Facebook investor…

Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox’s proprietary exosome technology Partnership…

With the offering of its first at-home testing kit, Forward expands COVID-19 testing options to scale its ability to treat the growing population experiencing the barricades of an overwhelmed healthcare system…

Psilocybin, the main psychoactive ingredient in magic mushrooms, has taken a step towards becoming a licensed treatment for depression, with the completion of the psychedelic chemical’s first controlled clinical study.

The newest primary care office in the nation’s capital opened just across the street from an upscale downtown development featuring luxury condos, designer boutiques from the likes of Carolina Herrera and a Tesla showroom.